J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wermeling, D.
Right arrow Articles by Rudy, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wermeling, D.
Right arrow Articles by Rudy, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration

DP Wermeling, JL Miller, SM Archer, JM Manaligod, and AC Rudy

The purpose of this study was to evaluate the pharmacokinetic profile of intranasal lorazepam in comparison to currently established administration routes. Eleven healthy volunteers completed this randomized crossover study. On three occasions, each separated by a 1-week washout, subjects received a 2 mg dose of lorazepam via the intranasal, intravenous, or intramuscular route. Blood samples were collected serially from 0 to 36 hours. Noncompartmental methods were used to determine pharmacokinetic parameters. Lorazepam was well absorbed following intranasal administration with a mean (%CV) bioavailability of 77.7(11.1). Intranasal administration resulted in a faster absorption rate than intramuscular administration. Elimination profiles were comparable between all three routes. The concentration-time profile for intranasal delivery demonstrated evidence of a double peak in several subjects, suggesting partial oral absorption. Females were found to have significantly higher AUC values than males for all three delivery routes. Overall, this study demonstrated favorable pharmacokinetics of intranasal lorazepam in relation to standard administration methods. Intranasal delivery could provide an alternative, noninvasive delivery route for lorazepam.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Child NeurolHome page
K. Sofou, R. Kristjansdottir, N. E. Papachatzakis, A. Ahmadzadeh, and P. Uvebrant
Management of Prolonged Seizures and Status Epilepticus in Childhood: A Systematic Review
J Child Neurol, August 1, 2009; 24(8): 918 - 926.
[Abstract] [PDF]

Home page
 PsychosomaticsHome page
P. W. Babington and D. R. Spiegel
Treatment of Catatonia With Olanzapine and Amantadine
Psychosomatics, December 1, 2007; 48(6): 534 - 536.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
J. Cloyd
Pharmacologic Considerations in the Treatment of Repetitive or Prolonged Seizures
J Child Neurol, May 1, 2007; 22(5_suppl): 47S - 52S.
[Abstract] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
U. Idrees and M. Londner
Pharmacotherapy Overview of Seizure Management in the Adult Emergency Department
Journal of Pharmacy Practice, October 1, 2005; 18(5): 394 - 411.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Clinical Pharmacology